Reuters logo
BRIEF-Fibrocell receives rare pediatric disease designation from FDA for FCX-013
June 12, 2017 / 12:09 PM / 6 months ago

BRIEF-Fibrocell receives rare pediatric disease designation from FDA for FCX-013

June 12 (Reuters) - Fibrocell Science Inc

* Fibrocell receives rare pediatric disease designation from FDA for FCX-013 for treatment of localized scleroderma

* Fibrocell Science Inc says expects to submit an investigational new drug application (IND) to FDA in Q4 of 2017 for FCX-013

* Fibrocell Science Inc says FCX-013 and FCX-007 are being developed in collaboration with intrexon Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below